TOCILIZUMAB ADMINISTERED IN DAILY CLINICAL PRACTICE - FINAL RESULTS OF THE GERMAN NON-INTERVENTIONAL STUDY "ROUTINE"

被引：0
|
作者：
Burmester, G. -R. [1 ]
von Hinueber, U.
Richter, C.
Schwenke, H.
Guertler, I.
Kaestner, P.
Peters, M. A. [2 ]
Iking-Konert, C. [3 ]
机构：
[1] Charite, Dept Rheumatol, D-13353 Berlin, Germany
[2] Roche Pharma AG, Grenzach Whylen, Germany
[3] Univ Clin Hamburg Eppendorf, Dept Med 3, Hamburg, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：452 / 452
页数：1
相关论文
共 50 条
  • [21] TOCILIZUMAB IN RHEUMATOID ARTHRITIS - ANNUAL INTERIM ANALYSIS OF THE GERMAN NON-INTERVENTIONAL STUDY ICHIBAN
    Specker, C.
    Kaufmann, J.
    Kellner, H.
    Bohl-Buehler, M.
    Schwenke, H.
    Vollmer, M. A.
    Kapelle, A.
    Zinke, S.
    Hofmann, M. W.
    Hellmann, P.
    Fliedner, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 879 - 879
  • [22] First interim analysis of the German prospective, non-interventional study PaVe: first results on the clinical routine of ruxolitinib in polycythemia vera
    Griesshammer, M.
    von der Heyde, E.
    Weide, R.
    Reichert, D.
    Weniger, J.
    Schlag, R.
    Hutzschenreuter, U.
    Becker, M.
    Just, M.
    Hacker, E.
    Cavanna, D.
    Lengfelder, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 148 - +
  • [23] Everolimus plus exemestane for HR plus advanced breast cancer in routine clinical practice-Final results from the non-interventional trial, BRAWO
    Lueftner, D.
    Schuetz, F.
    Schneeweiss, A.
    Grischke, E-M
    Bloch, W.
    Decker, T.
    Uleer, C.
    Salat, C.
    Foerster, F.
    Schmidt, M.
    Mundhenke, C.
    Tesch, H.
    Jackisch, C.
    Fischer, T.
    Guderian, G.
    Hanson, S.
    Fasching, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [24] PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
    Parhofer, Klaus G.
    von Stritzky, Berndt
    Pietschmann, Nicole
    Dorn, Cornelia
    Paar, W. Dieter
    DRUGS-REAL WORLD OUTCOMES, 2019, 6 (03) : 115 - 123
  • [25] PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
    Klaus G. Parhofer
    Berndt von Stritzky
    Nicole Pietschmann
    Cornelia Dorn
    W. Dieter Paar
    Drugs - Real World Outcomes, 2019, 6 : 115 - 123
  • [26] PREDICT (Patient Characteristics in REnal Cell Carcinoma and Daily PractICe Treatment With Sorafenib) Non-interventional Study - Final Report
    Jaeger, D.
    Ma, J.
    Korbenfeld, E.
    Zemanova, M.
    Leonhartsberger, N.
    Stauch, K.
    Boeckenhoff, A.
    Yu, J.
    Mardiak, J.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S520 - S520
  • [27] Efficacy and tolerability of glimepiride in daily practice - A non-interventional observational cohort study
    Scholz, GH
    Schneider, K
    Knirsch, W
    Becker, G
    CLINICAL DRUG INVESTIGATION, 2001, 21 (09) : 597 - 604
  • [28] TOCILIZUMAB, DMARDS AND GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS - INTERIM ANALYSIS OF THE GERMAN NON-INTERVENTIONAL STUDY ICHIBAN
    Specker, C.
    Kaufmann, J.
    Vollmer, M. A.
    Kellner, H.
    Hoehle, M.
    Kuehne, C.
    Volberg, C.
    Henes, J. C.
    Zinke, S.
    Moosig, F.
    Bohl-Buehler, M.
    Sieburg, M.
    Aringer, M.
    Hofmann, M. W.
    Hellmann, P.
    Fliedner, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 494 - 495
  • [29] PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: results in patients with and without diabetes
    Parhofer, K. G.
    von Stritzky, B.
    Pietschmann, N.
    Paar, W.
    DIABETOLOGIA, 2018, 61 : S559 - S560
  • [30] Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study.
    Schulz, Holger
    Janssen, Jan
    Strauss, Uwe P.
    Langen, Markus
    Dworschak, Kai Uwe
    Fiala-Buskies, Sabine
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345